<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400058</url>
  </required_header>
  <id_info>
    <org_study_id>GAM10-10</org_study_id>
    <nct_id>NCT04400058</nct_id>
  </id_info>
  <brief_title>Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression</brief_title>
  <official_title>Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to&#xD;
      evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in&#xD;
      patients with severe Coronavirus disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stabilization or Improvement in Clinical Status</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of subjects with stabilized or improved clinical status at Day 7 on at least one category on a 6-point clinical status scale.&#xD;
Clinical status categories will be defined as:&#xD;
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).&#xD;
Hospitalization, not requiring supplemental oxygen.&#xD;
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).&#xD;
ICU/hospitalization, requiring NIV/HFNC therapy.&#xD;
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.&#xD;
Death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive Clinical Status Analysis</measure>
    <time_frame>7 days</time_frame>
    <description>Change from Baseline (Day 1) at Day 7 in terms of the 6-point clinical status scale (descriptive analysis).&#xD;
Clinical status categories will be defined as:&#xD;
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).&#xD;
Hospitalization, not requiring supplemental oxygen.&#xD;
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).&#xD;
ICU/hospitalization, requiring NIV/HFNC therapy.&#xD;
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status Assessment</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of subjects with maintenance or improvement by at least one category on the 6-point clinical status scale on Day 14. (This endpoint will go into formal hypothesis testing procedure)&#xD;
Clinical status categories will be defined as:&#xD;
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).&#xD;
Hospitalization, not requiring supplemental oxygen.&#xD;
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).&#xD;
ICU/hospitalization, requiring NIV/HFNC therapy.&#xD;
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Initiation</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Proportion of subjects requiring invasive mechanical ventilation by Day 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Duration</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Duration of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 Test Result</measure>
    <time_frame>7 days</time_frame>
    <description>Results of RT-PCR for SARS-CoV-2 from nares/throat swab and/or sputum and/or lower respiratory tract sample on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all AEs</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of all AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs considered related to the IMP</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of AEs considered related to the IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological findings (chest CT/chest X-ray)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Radiological findings (chest CT/chest X-ray)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>Up to 33 daya</time_frame>
    <description>Change from baseline in blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood calcium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in carbon dioxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total protein</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in alanine transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in aspartate aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in PT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTT</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in PTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hsCRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgM</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFE</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IFE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in red blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hemoglobjn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin concentration</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell distribution width</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in red cell distribution width</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in white blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell differential</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in white blood cell differential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean platelet volume</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean platelet volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet distribution width</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in platelet distribution width</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in SpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A-a gradient</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in A-a gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiration Rate</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in respiration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in body temperature</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Octagam 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octagam 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octagam 10%</intervention_name>
    <description>Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days</description>
    <arm_group_label>Octagam 10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult aged ≥18years old&#xD;
&#xD;
          2. Provide voluntary, fully informed written and signed consent before any study-related&#xD;
             procedures are conducted&#xD;
&#xD;
          3. Able to understand and comply with the relevant aspects of the study protocol&#xD;
&#xD;
          4. Laboratory (RT-PCR) confirmed COVID-19 infection on throat swab and/or sputum and/or&#xD;
             lower respiratory tract samples&#xD;
&#xD;
          5. Hospitalized with a resting room-air SpO2 of ≤93% or PaO2/FiO2 ratio &lt;300mmHg.&#xD;
             Measurement can be taken from documented source records in the 24 hours prior to&#xD;
             screening&#xD;
&#xD;
          6. Chest imaging confirming lung involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Existence of other evidence that can explain pneumonia including but not limited to:&#xD;
             Influenza A virus, influenza B virus, bacterial pneumonia (as suggested by the&#xD;
             combined clinical picture, radiological findings and known laboratory results [eg,&#xD;
             elevated procalcitonin &gt;0.5ng/mL and concomitant neutrophilia]), known fungal&#xD;
             pneumonia, suspected fungal pneumonia based on compromised immune system with a&#xD;
             history of past fungal infections, noninfectious causes, etc.&#xD;
&#xD;
          2. Known history of serious allergic reactions, including anaphylaxis, to IVIG or its&#xD;
             preparation components&#xD;
&#xD;
          3. Subjects with a history of thromboembolic event (TEE) within the last 12 months, such&#xD;
             as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke,&#xD;
             transient ischemic attack, peripheral artery disease (Fontaine IV)&#xD;
&#xD;
          4. Subjects with an underlying medical condition that can lead to hypercoagulable states&#xD;
             and hyperviscosity such as antithrombin III deficiency, Factor V Leiden, Protein C&#xD;
             deficiency, antiphospholipid syndrome and malignancy&#xD;
&#xD;
          5. Known history of selective IgA deficiency with antibodies against IgA&#xD;
&#xD;
          6. Subjects with conditions such as human immunodeficiency virus (HIV) infection, known&#xD;
             acute or chronic hepatitis B or C (HBsAg positive or HCV ribonucleic acid (RNA) PCR&#xD;
             positive or currently treated with antivirals), pulmonary fibrosis, elevated&#xD;
             procalcitonin (&gt; 0.5) with concomitant neutrophilia (elevated polys), heparin induced&#xD;
             thrombocytopenia (HIT), and moderate to severe renal dysfunction (per investigator&#xD;
             discretion based on estimated glomerular filtration rate [eGFR] &lt;59 mL/min/1.73 m2, as&#xD;
             defined by KDIGO Clinical Practice Guideline):&#xD;
&#xD;
               -  Moderately reduced GFR (G3a): GFR = 45 to 59 ml/min/1.73 m2&#xD;
&#xD;
               -  Moderately reduced GFR (G3b): GFR = 30 to 44 ml/min/1.73 m2&#xD;
&#xD;
               -  Severely reduced GFR (G4): GFR = 15 to 29 ml/min/1.73 m2&#xD;
&#xD;
               -  Kidney failure (G5): GFR &lt;15 ml/min/1.73 m2&#xD;
&#xD;
          7. Currently requiring IMV (invasive mechanical ventilation or having received IMV during&#xD;
             the last 30 days&#xD;
&#xD;
          8. Known clinically significant preexisting lung, heart, or neuromuscular disease that,&#xD;
             in the investigator's opinion, would impact subject's ability to complete study or may&#xD;
             confound the study results&#xD;
&#xD;
          9. Body weight &gt;125 kg&#xD;
&#xD;
         10. Women who are pregnant or breast-feeding&#xD;
&#xD;
         11. Subjects who received COVID-19 convalescent plasma, IVIG products, anti-interleukin&#xD;
             agents (eg, Tocilizumab), or interferons for their COVID-19 disease before enrollment&#xD;
             or plan to receive this treatment during the course of the study&#xD;
&#xD;
         12. Enrolled in other experimental interventional studies or taking experimental&#xD;
             medications (ie, convalescent plasma). Diagnostic studies can be allowed if the&#xD;
             anticipated total blood volume to be drawn across both studies and for therapeutic&#xD;
             purposes does not exceed 450 mL over any 8-week period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Ryazan'</city>
        <zip>390000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Kremenchuk</city>
        <zip>39623</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

